(See sidebar for Head & Neck PET Request Form.)
Eligibility criteria: PET for the evaluation of metastatic squamous cell carcinoma in neck nodes when the primary disease site is unknown after standard radiologic and clinical investigation
Note: a panendoscopy is NOT required prior to the PET scan
Nasopharyngeal (baseline staging)
Eligibility criteria: PET for the staging of nasopharyngeal cancer
Note: for cervical esophageal cancer, see Gastrointestinal Cancers.
Head & Neck node positive (baseline staging)
Eligibility criteria: PET for the baseline staging of node positive (N1-N3) H&N cancer where PET will impact radiation therapy (e.g., radiation volume or dose)
Head & Neck (re-staging after chemoradiotherapy)
Eligibility criteria: PET to assess patients with N1-N3 metastatic squamous-cell carcinoma of the head and neck after chemoradiation (HPV negative); or who have residual neck nodes equal to or greater than 1.5 cm on re-staging CT performed 10 to12 weeks post therapy (HPV positive).
Eligibility criteria: PET where recurrent or persistent disease is suspected on the basis of elevated and/or rising tumour markers (e.g., thyroglobulin) with negative or equivocal conventional imaging work-up.
Anaplastic Thyroid (staging)
Eligibility Criteria: PET for the staging of histologically proven anaplastic thyroid cancer with negative or equivocal conventional imaging work-up.
Medullary Thyroid (staging & recurrent)
Eligibility Criteria: PET for the baseline staging of histologically proven medullary thyroid cancer being considered for curative intent therapy or where recurrent disease is suspected on the basis of elevated and/or rising tumour markers (e.g., calcitonin) with negative or equivocal conventional imaging work-up.
Esophageal or GE Junction
Eligibility Criteria: PET for baseline staging assessment of those patients diagnosed with esophageal/GE Junction cancer being considered for curative therapy and/or repeat PET/CT scan on completion of pre-operative/ neoadjuvant therapy, prior to surgery; or for re-staging of patients with locoregional recurrence, after primary treatment, being considered for definitive salvage therapy.